TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05336487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 2 hours of physical activity per day, 5 days per week, for the intervention period
Study: NCT04435054

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.
Description: Non-invasive blood biological tests - NAFLD Fibrosis Score, FIB-4, Fibrotest, FibrometerNAFLD~Non-invasive imaging:~- Transient elastography (FibroScan), Shear Wave imaging, Magnetic resonance imaging (MRI-PDFF and MRE) in a subgroup of participants.
Study: NCT05529238

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: biofeedback training
Description: participants received biofeedback training for kegel exercises in the supervised group. the unsupervised group practised their Kegel exercises at home
Study: NCT03221205

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Description: CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (measured at the nasal mask) via a resistance to assure the lack of distal pressure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Description: Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
Study: NCT04511156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foundational Helping Skills
Description: Each site will implement three waves of Foundational Helping Skills training. Each training will include 12 trainees each, with a minimum of 2 trainers per training. Each site will include pre and post research days, where they will collect primary and secondary outcomes with support from research staff (trained raters, actors, and qualitative researcher). Each site will qualitatively assess the training after the first wave to identify any areas for modification, and after the second and third waves to develop recommendations for future implementation.
Study: NCT02244762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg HC-ER
Description: 1-72 hours
Study: NCT03740165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study: NCT03947385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: IDE196 dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: IDE196 dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: IDE196 dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: IDE196 dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: IDE196 dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: IDE196 dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: IDE196 dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: IDE196 dosed orally, twice daily for each 28-day cycle
Study: NCT00916214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Description: The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
Study: NCT01158664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.6 mm tread pitch implant
Description: 0.6 mm tread pitch implant will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.1 mm tread pitch implant
Description: 0.1 mm tread pitch implant will be used
Study: NCT01315236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation (LAI)
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: * Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.
Study: NCT03947385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib dosed orally, twice daily for each 28-day cycle
Study: NCT02244762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg HC-ER
Description: 1-72 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg HC-ER
Description: 1-72 hours
Study: NCT03947385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib dosed orally, twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib dosed orally, twice daily for each 28-day cycle
Study: NCT04255043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS guidance
Description: IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography guidance
Description: DCB (Sequent® Please) treatment
Study: NCT02931630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein powder
Description: 60 g of whey protein powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein powder
Description: 60 g of whey protein powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maltodextrin powder
Description: 60 g of Maltodextrin powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maltodextrin powder
Description: 60 g of Maltodextrin powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber bread
Description: Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber bread
Description: Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
Study: NCT01704781

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide placebo
Description: Capsules are identical to the active Lenalidomide capsules used.
Study: NCT02931630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fiber bread
Description: Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fiber bread
Description: Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
Study: NCT03658434

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Description: Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
Study: NCT04164030

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Exercise Program for Adults with Type 2 Diabetes
Description: Eating Smart and Being Active program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education plus Occupational Therapy plus Yoga
Description: multimodal interdisciplinary approach
Study: NCT04483895

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube insertion
Description: ETT was inserted and the depth was estimated by either OHL method or 7-8-9 method

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube insertion
Description: ETT was inserted and the depth was estimated by either OHL method or 7-8-9 method
Study: NCT05493358

Intervention type: PROCEDURE
Intervention: Laparoscopic distal gastrectomy
Description: Distal gastrectomy and standard D2 lymphadenectomy
Study: NCT03576053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine intradermal injection
Study: NCT03196089

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Oxygen application
Description: Supplemental oxygen via mask

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen application
Description: Supplemental oxygen via mask
Study: NCT04362254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab
Study: NCT04190446

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00696475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00689091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitor
Description: Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic MAC alert
Description: Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
Study: NCT02929784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Device: neuroConn_CE_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
Study: NCT01704781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vacc-4X
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
Study: NCT02929784

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: no meaningful stimulation will be given.
Study: NCT04728672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Kinesio Tape

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Micropore Tape
Description: Micropore Tape
Study: NCT01759888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DTBZ
Description: Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
Study: NCT03508427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily self-monitoring
Description: Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
Study: NCT00145678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy
Description: Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Community Care
Description: individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
Study: NCT02625883

Intervention type: OTHER
Intervention: Interview
Description: Interview by validated Quality-of-life-questionnaire
Study: NCT03899688

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary sinus augmentation
Description: Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation
Description: Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
Study: NCT00797368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Exercise
Description: Manual Therapy and Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises
Description: Home exercises
Study: NCT02644200

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin tannate
Study: NCT01182779

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion
Description: Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Protons
Description: Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E.
Study: NCT01704781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vacc-4X
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vacc-4X
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuGM-CSF
Description: Granulocyte macrophage colony stimulating factor as a local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuGM-CSF
Description: Granulocyte macrophage colony stimulating factor as a local adjuvant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhuGM-CSF
Description: Granulocyte macrophage colony stimulating factor as a local adjuvant
Study: NCT03591796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFOV
Description: Ventilated infants were randomized to HFOV

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMV
Description: Ventilated infants were randomized to CMV.
Study: NCT04190446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00999128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Oral repeating dose
Study: NCT03481764

Intervention type: GENETIC
Intervention: HRC-test
Description: Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used.

Intervention type: GENETIC
Intervention: HRC-test
Description: Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used.

Intervention type: GENETIC
Intervention: HRC-test
Description: Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used.
Study: NCT01564771

Intervention type: OTHER
Intervention: Non Intervention
Description: This Is A Non Interventional Study
Study: NCT02821910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
Description: High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
Description: 1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
Study: NCT01312350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant docetaxel/cisplatin/fluorouracil
Description: 2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No treatment before definitive CCRT
Description: concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
Study: NCT00500045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: niacin 1500 mg po qd
Study: NCT00282165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naratriptan
Description: four weeks double blind experimental treatment using oral naratriptan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: four weeks double blind placebo treatment
Study: NCT02512263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based training program
Description: A home-based training program of 8 exercises to do 5 times a week during 9 weeks
Study: NCT00798967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide
Description: 0.05 mg/kg/day sc injection for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
Study: NCT03576053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Skin Prick Test with Histamine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Skin Prick Test with Histamine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: Manually skin insertion of cowhage spicules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: Manually skin insertion of cowhage spicules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stimulation
Description: Short heat stimulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Heat stimulation
Description: Short heat stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-heating
Description: Mild skin pre-heating

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serotonin
Description: Serotonin electrophoresis
Study: NCT04204590

Intervention type: OTHER
Group type: OTHER
Intervention: Deprescribing algorithm
Description: For this study an implicit, evidence-supported and patient-centred algorithm has been developed. The outcome of the algorithm is an advice to the doctor to deprescribe or not deprescribe the statin and/or PPI.
Study: NCT01000870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNI-513-01
Description: Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.